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Abstract
Endometriosis is a common estrogen dependent and inflammatory disease affect-
ing approximately 176 million women worldwide. Currently, the time between onset 
of symptoms and a definitive diagnosis has been reported by several international 
studies to range from 6 to 12 years. Presently, laparoscopic surgery followed by histo-
pathological confirmation of lesions remains the gold standard for diagnosis. In part 
because of cost and invasiveness, current trends favor reduced laparoscopic surgeries 
in preference of the non-surgical diagnosis of endometriosis. However, the search for 
a clinical marker or markers of endometriosis that provide equal or similar sensitivity 
and specificity to laparoscopy has remained elusive. Thus, the search for a diagnostic 
test for the diagnosis of endometriosis continues to be a high priority research and 
clinical issue. Recent studies have reported favorable results with microRNA; how-
ever, lack of replication and absence of validation suggest that circulating miRNA 
may not be reliable for clinical use. Use of different screening platforms together with 
divergent methods may account for some of the lack or reproducibility in the litera-
ture. Herein we critically assess the recent literature and explore sources for discrep-
ant findings. We suggest that prospective studies using validated reference miRNA 
to normalize results together with improved study design may yet reveal a suitable 
diagnostic marker or panel of markers for the diagnosis of endometriosis.
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1. Background
Endometriosis is a common estrogen dependent and progesterone resistant 
disease of unknown cause characterized by growth of endometrial cells outside 
the uterine cavity [1]. It is estimated that 6–11% of all women are affected by 
endometriosis reaching an estimated 176 million women globally [2]. A chronic 
painful disease [3], endometriosis causes substantial health distress and interfer-
ence with normal activities including work resulting in an average loss of 10.8 h/
week from work [2] all leading to diminished quality of life (QOL) for affected 
women and their families. Chronic pelvic pain and infertility are common symp-
toms of endometriosis that bring women with this disease to seek medical atten-
tion. Approximately 71–87% of all women experiencing chronic pelvic pain and 
50% of infertile women are diagnosed with endometriosis [4]. Thus, women with 
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endometriosis report significant health distress and interference with normal activi-
ties including work and leisure time activities all leading to a deleterious effect upon 
women’s social functioning, emotional well-being, employment, and vitality [5].
An important obstacle to the timely diagnosis and effective management of 
endometriosis is the lack of a simple diagnostic test. Diagnosis has been reported to be 
delayed by between 6 and 12 years with an average of 9 years from the onset of symp-
toms to definitive diagnosis [6]. Hence, identification of a clinical tool for the diagnosis 
of endometriosis has become a high priority research objective [2, 7, 8]. Health care 
providers and patients face a number of challenges in arriving at a diagnosis of endome-
triosis including: early age at onset of symptoms, normalization of pain by primary care 
providers, and suppression of symptoms through intermittent use of oral contraceptive 
pills [9]. Symptoms of endometriosis are shared with many other diseases including 
autoimmune diseases, cancer, irritable bowel syndrome (IBS), and musculoskeletal 
abnormalities. Therefore, an ideal biomarker of endometriosis must differentiate 
between endometriosis and other explanations for patient symptoms. In addition, 
clinical markers should be as minimally invasive as possible, affordable and convenient 
to use with the added benefit of providing insight into potential treatment response. 
Furthermore, the ideal biomarker must provide equivalent or similar outcome measures 
of sensitivity, specificity, positive, and negative predictive values to laparoscopy.
Currently, the gold standard for diagnosis remains visualization of endometri-
otic lesions typically by laparoscopy followed by histopathological confirmation of 
disease [10]. Current trends favoring the non-surgical diagnosis of endometriosis 
increase the pressure to identify novel clinical markers of endometriosis. Despite a 
plethora of biochemical differences in the peripheral circulation, peritoneal fluid, 
and endometrial tissues of women with endometriosis compared to healthy controls, 
no marker has been found with adequate sensitivity or specificity to challenge lapa-
roscopy for the diagnosis of endometriosis whether used alone or in a panel of clinical 
markers [11–16]. However, reports of promising results have been brought forward in 
the literature from which epigenetic markers are potentially the most exciting.
2. Candidate clinical markers of endometriosis
Multiple gene and protein expression levels have been documented in women 
with endometriosis compared to controls; however, none have yielded reliable 
clinical markers of disease. Recent studies investigating the mechanisms controlling 
gene expression have produced promising results. Several histone modifications 
have been associated with endometriosis. For example, endometriotic stromal cells 
(ESC) have a lower global acetylation level of H3, and histone deacetylases 1 and 2 
(HDAC1 and HDAC2) were upregulated compared to women without endometrio-
sis [17]. Furthermore, histone deacetylase inhibitor (HDACI) treatment promoted 
apoptosis by reactivating the silenced chromatin [18]. G-protein-coupled estrogen 
receptor (GPER) expression and proliferation of endometriotic cells was inhibited 
by treatment with the HDACI’s romidepsin and vorinostat [19]. These data suggest 
that histone modifications are involved in the pathophysiology of endometriosis 
and that HDACI’s are promising agents for endometriosis treatment. However, use 
of histone markers in the diagnosis of endometriosis has yet to be explored.
Long-chain non-coding RNA (lnc-RNAs) are 200–100,000 bp RNA molecules 
which do not encode for protein, but are involved in transcriptional and post-
transcriptional regulation of gene expression [20]. They are the most common non-
coding RNAs and are involved in cell proliferation, differentiation, and apoptosis; 
all processes central in the pathobiology of endometriosis [21]. Some lnc-RNAs 
proposed as diagnostic markers of endometriosis include: H19 [22], CHL1-AS2 
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[23, 24], AC002454.1 [25], lncRNA SRA (steroid receptor RNA activator) [26], 
MALAT-1 [27], and LINC01279 [28]. Results of a recent study revealed the lnc-RNA 
are carried in circulating extracellular vesicles in women with endometriosis [29]. 
However, use of lnc-RNAs in the diagnosis of endometriosis has not been evaluated 
in a prospective study of women with symptoms suggestive of endometriosis with 
an independent validation step and thus their clinical utility remains uncertain.
Several recent studies have documented aberrant expression of multiple 
microRNAs (miRNAs) in the eutopic and ectopic endometrium of women with 
endometriosis [30–37]. miRNAs are short non-coding RNAs, 19–25 nucleotides 
long, that negatively regulate mRNA translation by repressing the protein transla-
tional machinery or degrading their target transcripts. Greater than 2000 mature 
human miRNA sequences have been identified and are thought to regulate approxi-
mately 50% of all protein coding genes. Multiple recent studies have documented 
differential microRNA (miRNA) expression in endometriotic tissues compared 
to eutopic endometrium of women with endometriosis and controls [33, 38–40]. 
miRNA are thought to hold promise as diagnostic biomarkers of disease because 
they are post-transcriptional regulators of gene expression that are stably expressed 
over time in bodily fluids and tissues [41]. Briefly, miRNA regulate protein expres-
sion through binding to and inhibiting the translation of mRNA transcripts into 
protein [42]. miRNAs are synthesized in the cytoplasm from nucleic hairpin 
intermediates (pre-miRNA) [43] which are then processed to yield mature miRNA 
that resist RNase degradation [41]. miRNA form an RNA-induced silencing complex 
(RISC) with Argonaute, Dicer, TAR RNA binding protein (TRBP) and protein 
activator of PKR (PACT) to post-transcriptionally regulate genes by binding to the 
3′ region of the mRNA transcript and inhibiting translation [44].
In the early 2000s, several studies proposed that circulating levels of miRNA are 
differentially expressed in women with endometriosis compared to controls and 
thus could have diagnostic value [30, 31, 45]. Different methods including in situ 
hybridization, targeted RT-PCR and several different screening platforms includ-
ing miRNA based microarrays, next generation sequencing and bio-informatics 
followed by RT-PCR validation have subsequently revealed a broad spectrum of 
miRNAs that are differentially expressed in women with endometriosis compared 
to control groups [29–31, 45–56]. However, to date, only the results for hsa-miR-
451a [47, 48], 199a-5p [31, 54] and hsa-miR-141-3p [31, 49] have been successfully 
replicated in more than one study (Table 1). For the vast majority of miRNAs, 
differential expression has only been reported in a single study or the results for a 
few miRNAs have not been replicated by other investigators. For example, circu-
lating levels of hsa-miR-145 were lower in women with endometriosis compared 
to controls [31] whereas hsa-miR-145 levels did not differ [47] or were higher in 
women with endometriosis compared to the control groups [50]. We postulate that 
divergent results may be the consequence of different screening platforms and tech-
nologies used to identify candidate miRNA markers of disease [57–59] and control 
group characteristics. Moreover, we suggest that different reference material used to 
quantify circulating miRNA levels are an additional source of variation.
While RNU6 has been widely used in the general miRNA literature to normal-
ize miRNA expression in tissue, abundance and stability of expression have not 
been evaluated for circulating miRNA expression in women with endometriosis. 
Furthermore, RNU6 has low stability and abundance that is greatly influenced by 
sample storage and processing and the Cp values of RNU6 are highly variable from 
miRNA Cp values [51, 60, 61]. Similarly, the abundance and stability of miR-16-5p 
levels in the serum of women with endometriosis is uncertain but variable from the 
Cp values of miRNA targets [51]. Furthermore, circulating levels of miR-16-5p are 
altered by inflammation and stress [62, 63] and thus we suggest that both RNU6 
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Fluid Case/
control 
(N)
Cases Controls Reference 
miRNA
Cycle 
stage
Differentially 
expressed 
hsa-miR’s
Citation
Serum 60/25 Stages 
I–IV
Symptomatic RNU6 NS ↑199a and 
122, ↓9*, 145*, 
141*, and 
542-3p
[31]
Serum 24/24 Stage 
III and 
IV
Symptomatic RNU6 P vs. S ↓let-7b, c, d, e, 
f (P) and 135a 
(S)
[46]
Serum 24/24 Stage 
III and 
IV
Symptomatic RNU6 NS ↓3613-5p 
and 6755-3p 
↑18a-5p, 125b-
5p, 143-3p, 
150-5p 342-3p, 
451a and 
500a-3p
[47]
Serum 41/40 Stages 
I–IV
Symptomatic 
(n = 20) 
and Healthy 
(n = 20)
RNU6 NS ↑451a [48]
Serum 30/20 Stages 
I–II
Infertile cel-miR-39 ND ↓30c-5p, 
127-3p, 99b-
5p, 15b-5p, 
20a-5p, and 
↑424-3p, 
185-5p
[52]
Serum 45/35 Stages 
I–IV
Symptomatic RNU6 ND ↑122 and 199a [54]
Serum 40/25 Stages 
I–IV
Healthy 18 s 
mRNA
ND ↓199a-5p [55]
Plasma 23/23 Stage 
III and 
IV
Symptomatic miR-16 ND ↓17-5p, 20a 
and 22
[30]
Plasma 61/30 Stages 
I–IV
Symptomatic 
(n = 35) 
and Healthy 
(n = 30)
miR-30e 
and 99a
NS ↓200a-3p and 
141-3p
[49]
Plasma 55/23 Stages 
I–IV
Symptomatic miR-
103-3p
ND ↑145 (stages 
I and II), 
↓31(stages 
I–IV)
[50]
Plasma Variable Stage 
I–IV
Symptomatic 
(n = 8–39) 
Healthy 
(n = 8)
RNU6 vs. 
miR-16 vs. 
miR-30b
NS ↓139-3p, 155 
and 574-3p
[51]
Plasma 51/41 Stages 
I–IV
Symptomatic miR-
106a-5p, 
199a-3p, 
150-5p, 
425-5p, 
125a-5p, 
and 
30e-5p
NS ↓miR154-5p 
and 378a-3p, 
↑196b-5p and 
33a-5p
[53]
Plasma 60/30 Stages 
I–IV
Symptomatic miR-28-3p 
and 
423-3p
S *125b-5p, 
28-5p, 29a-3p
[56]
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and miR-16-5p are not suitable for normalization of circulating miRNA levels in 
women with endometriosis.
3. Effect of reference miRNA used to normalize results
While serum RNU6 has been widely used as the reference miRNA in prior 
endometriosis studies [29, 31, 46–48, 54], its levels have previously been reported 
to be unstable, unreliable, and a poor reference for miRNA since it is not processed 
or protected in the same way as miRNA [61, 63]. Therefore, we suggest that choice 
of reference miRNA can influence ability to detect significant differences and 
the direction of significant differences elicited. Previous studies report that hsa-
miR-451a is upregulated in women with endometriosis compared to symptomatic 
controls [47] and compared to both symptomatic and asymptomatic (healthy) 
control groups [48]. Both prior studies employed RNU6 as a reference. While hsa-
miR-451a has been found to act as a tumor suppressor [64, 65], it is also a marker 
of hemolysis [66] and thus we suggest that care should be employed to exclude 
samples with hemolysis before analysis. The miRNA ratio of hsa-miR-451a and hsa-
miR-23a-3p has been employed by others [56, 67] to monitor for sample hemolysis. 
Therefore, we suggest that hsa-miR-451a has limited value as a candidate marker of 
endometriosis.
4. Effect of control group definition
Several studies have employed healthy women as their control population 
[29, 45, 48, 49, 51, 55], thus allowing circulating miRNA levels in women with 
endometriosis to be compared to symptomatic and asymptomatic healthy control 
populations. While the majority of previous reports employed symptomatic 
controls [30, 31, 46–51, 53, 54, 56], hsa-miR-16-5p [30, 51] RNU6 (the most com-
mon) reference material used to normalize miRNA expression [31, 46–48, 51, 54]; 
reference materials that are unsuitable for normalizing serum miRNA expression. 
In our experience, differential miRNA expression was dependent upon whether 
comparisons were made with asymptomatic compared to symptomatic controls. 
Therefore, we suggest that control group characteristics on the differential 
Fluid Case/
control 
(N)
Cases Controls Reference 
miRNA
Cycle 
stage
Differentially 
expressed 
hsa-miR’s
Citation
Plasma 33/20 NR Healthy miR-132 NR ↑15b, 16, 191, 
195, 1973, 
1979, and 
4284
[45]
Plasma 6/4 Stages 
III–IV
Healthy RNU6 NR ↓375, 27a-3p, 
and 30d-5p
[29]
miRNA in bold have been replicated by at least one other group of investigators.
S = significant effect of menstrual cycle stage, NS = not significant, ND = not determined, NR = not reported, 
differential miR expression was either increased (↑) or decreased (↓) in women with endometriosis compared to 
controls.
*Direction could not be ascertained from the published report.
Table 1. 
Summary of miRNA’s differentially expressed by microarray and RT-PCR in women with endometriosis 
(cases) compared to controls.
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expression of candidate miRNA in women with endometriosis merits further 
investigation.
While, lack of replication, absence of validation of results, and poor sensitiv-
ity and specificity currently limit the value of miRNA as diagnostic markers of 
endometriosis [51], we propose that usefulness of miRNA for the diagnosis of 
endometriosis cannot be evaluated without appropriate determination of appropri-
ate reference miRNA.
5. Future directions
Although identification of clinical markers of endometriosis has long been sought, 
none has so far been suitable to displace laparoscopy as the gold standard for diagno-
sis. Endometriosis is a complex heterogenous disease with variable presentation whose 
symptoms are easily confused with other clinical problems. Since endometriosis is 
detectable with high frequency amongst asymptomatic women [68] surgical exclusion 
of disease in the control group is essential to prevent biasing results towards the null. 
Consequently, we suggest that control or reference group definition is important. 
Numerous prior studies reporting differential miRNA expression in women with 
endometriosis have employed asymptomatic women as their reference population 
[29, 45, 48, 49, 51, 55]. However, healthy women without symptoms of endometriosis 
and without evidence of endometriosis by laparoscopy (asymptomatic control) and 
symptomatic women without evidence of disease at the time of laparoscopy (symp-
tomatic control) are functionally different, yet both groups continue to be employed 
as controls in contemporary studies. Results from our laboratory suggest that inclu-
sion of asymptomatic controls can produce misleading results and thus speculate that 
restricting the control group to symptomatic controls in future studies may improve 
reproducibility of results. In addition to control group, we propose that the use of vali-
dated reference miRNA to normalize results also affects detection of levels of miRNA 
differentially expressed in women with endometriosis compared to controls.
Having identified candidate miRNA for the diagnosis of endometriosis it will be 
important to determine their relationship with pelvic pain as well as response to treat-
ment. In the absence of this data the potential prognostic value of candidate markers 
of endometriosis remains uncertain. We also propose that future studies with robust 
sample size will be needed to clarify the relationship between circulating miRNA lev-
els and menstrual cycle phase. Studies reporting menstrual cycle stage and circulating 
miRNA levels are thus far have produced equivocal results [31, 46–49, 51, 53, 56]. 
Furthermore, lesion type (endometrioma, peritoneal endometriosis, deep infiltrating 
endometriosis) are biologically distinct and thus a single clinical marker is unlikely to 
be dysregulated in all lesion types and thus a panel of markers may be more relevant. 
Furthermore, duration of disease and age of lesion may also present with functional 
differences. Therefore, discovery of clinical markers should describe the lesion types 
present in study participants. The influence of study participant age and body mass 
index are also important variables associated with pelvic pain and disease severity 
that are frequently not considered in analyses of clinical markers of endometriosis. 
Finally, the functional role of candidate markers in endometriosis has the potential to 
suggest therapeutic targets for additional research.
6. Summary and conclusions
Use of reference miRNA that may not be ideal for normalization of results may 
account for noted weaknesses in the literature. Use of validated reference miRNA 
7microRNA and Overcoming the Challenges of Their Use in the Diagnosis of Endometriosis
DOI: http://dx.doi.org/10.5772/intechopen.91324
Author details
Victoria Turpin1, Anna Leonova1, Sanjay K. Agarwal2 and Warren G. Foster1,2*
1 Department of Obstetrics and Gynecology, McMaster University, 
Hamilton, Ontario, Canada
2 Department of Obstetrics, Gynecology and Reproductive Sciences, University of 
California, San Diego, California, United States of America
*Address all correspondence to: fosterw@mcmaster.ca
markers and careful control of sample condition for potential confounders should 
improve study replication. Finally, although circulating miRNA levels have low 
variability in women with endometriosis, it will be necessary for discovery phases 
to include a large number of study participants to control for participant age, 
menstrual cycle stage, BMI, stage of disease, and type of lesions. Thus, we suggest 
that despite set-backs with reproducibility of results, it may be too soon to judge the 
diagnostic potential of miRNA.
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